📊 VREOF Key Takeaways
Is Vireo Growth Inc. (VREOF) a Good Investment?
Vireo Growth demonstrates exceptional revenue growth of 170.4% YoY, reaching $268.8M, but remains deeply unprofitable with a -25.3% net margin and -$68.1M net loss. Despite adequate liquidity and low leverage, the company's negative free cash flow of -$24.6M indicates structural cash burn that threatens sustainability without an imminent path to profitability.
Vireo Growth Inc. Key Strengths (VREOF)
- Exceptional revenue growth of 170.4% YoY demonstrates strong market demand
- Healthy gross margin of 47.3% indicates viable core product economics
- Strong balance sheet with low debt-to-equity ratio of 0.19x and $102.2M cash reserves
VREOF Stock Risks: Vireo Growth Inc. Investment Risks
- Massive net losses of -$68.1M with -25.3% net margin despite revenue scale
- Negative free cash flow of -$24.6M driven by high capital expenditure burn
- Inability to achieve profitability at $268.8M revenue scale suggests structural business model challenges
- Zero insider Form 4 filings in past 90 days indicates lack of management conviction
Key Metrics to Watch
- Quarterly path to operating profitability and timeline to positive net income
- Free cash flow trend and relationship between operating cash flow and capital expenditure
- Operating expense as percentage of revenue - whether OpEx can decline as percentage of growing revenue base
Vireo Growth Inc. (VREOF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Vireo Growth Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
VREOF Profit Margin, ROE & Profitability Analysis
VREOF vs Healthcare Sector: How Vireo Growth Inc. Compares
How Vireo Growth Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vireo Growth Inc. Stock Overvalued? VREOF Valuation Analysis 2026
Based on fundamental analysis, Vireo Growth Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vireo Growth Inc. Balance Sheet: VREOF Debt, Cash & Liquidity
VREOF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vireo Growth Inc.'s revenue has grown significantly by 394% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.16 indicates the company is currently unprofitable.
VREOF Revenue Growth, EPS Growth & YoY Performance
VREOF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $24.5M | -$6.5M | $-0.02 |
| Q3 2025 | $25.2M | -$4.9M | $-0.02 |
| Q2 2025 | $25.1M | -$668.4K | $0.00 |
| Q1 2025 | $24.1M | -$6.5M | $-0.02 |
| Q3 2024 | $24.7M | -$4.9M | $-0.02 |
| Q2 2024 | $20.2M | -$668.4K | $0.00 |
| Q1 2024 | $19.1M | -$6.7M | $-0.05 |
| Q3 2023 | $18.9M | -$5.2M | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vireo Growth Inc. Dividends, Buybacks & Capital Allocation
VREOF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vireo Growth Inc. (CIK: 0001771706)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VREOF
What is the AI rating for VREOF?
Vireo Growth Inc. (VREOF) has an AI grade of C with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VREOF's key strengths?
Claude: Exceptional revenue growth of 170.4% YoY demonstrates strong market demand. Healthy gross margin of 47.3% indicates viable core product economics.
What are the risks of investing in VREOF?
Claude: Massive net losses of -$68.1M with -25.3% net margin despite revenue scale. Negative free cash flow of -$24.6M driven by high capital expenditure burn.
What is VREOF's revenue and growth?
Vireo Growth Inc. reported revenue of $268.8M.
Does VREOF pay dividends?
Vireo Growth Inc. does not currently pay dividends.
Where can I find VREOF SEC filings?
Official SEC filings for Vireo Growth Inc. (CIK: 0001771706) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VREOF's EPS?
Vireo Growth Inc. has a diluted EPS of $-0.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VREOF's fundamental grade?
Based on our AI fundamental analysis in June 2026, Vireo Growth Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VREOF stock overvalued or undervalued?
Valuation metrics for VREOF: ROE of -22.2% (sector avg: 15%), net margin of -25.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VREOF's AI grade for 2026?
Our dual AI analysis gives Vireo Growth Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VREOF's free cash flow?
Vireo Growth Inc.'s operating cash flow is $3.7M, with capital expenditures of $28.3M. FCF margin is -9.2%.
How does VREOF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -25.3% (avg: 12%), ROE -22.2% (avg: 15%), current ratio 1.59 (avg: 2).